Top Page
Shield Therapeutics
(LSE:STX)
Shield Therapeutics (STX) vs. iShares MSCI United Kingdom ETF (EWC)
Shield Therapeutics Business Overview & Revenue Model
Shield Therapeutics Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 32.07M | 25.18M | 13.09M | 5.50M | 1.52M | 10.39M |
| Gross Profit | 14.32M | 10.57M | 4.03M | 2.00M | 539.00K | 9.03M |
| EBITDA | -9.93M | -16.58M | -30.29M | -46.07M | -17.69M | 820.00K |
| Net Income | -16.42M | -21.27M | -33.29M | -40.44M | -19.34M | -2.63M |
Balance Sheet | ||||||
| Total Assets | 62.10M | 45.90M | 48.80M | 22.07M | 44.41M | 32.53M |
| Cash, Cash Equivalents and Short-Term Investments | 10.81M | 5.61M | 13.95M | 2.82M | 12.12M | 2.94M |
| Total Debt | 27.05M | 21.06M | 20.41M | 6.10M | 156.00K | 28.00K |
| Total Liabilities | 76.96M | 46.95M | 26.49M | 16.65M | 3.38M | 2.25M |
| Stockholders Equity | -14.86M | -1.05M | 11.79M | 5.43M | 40.69M | 30.28M |
Cash Flow | ||||||
| Free Cash Flow | -8.15M | -7.03M | -40.07M | -20.14M | -18.80M | -1.42M |
| Operating Cash Flow | -8.15M | -7.01M | -37.13M | -18.25M | -16.74M | -1.40M |
| Investing Cash Flow | -1.30M | -1.89M | -2.43M | -1.70M | -2.05M | -20.00K |
| Financing Cash Flow | 11.83M | 4.21M | 49.66M | 7.71M | 27.58M | -47.00K |
Shield Therapeutics Technical Analysis
Shield Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | £3.89B | 13.61 | 15.66% | 4.09% | 3.73% | 27.13% | |
57 Neutral | £171.09M | -7.00 | 2.83% | 2.09% | 8.74% | -166.50% | |
56 Neutral | £552.73M | ― | ― | ― | 4.50% | 74.32% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | £73.26M | -3.71 | -396.71% | ― | 93.48% | 51.18% |
Shield Therapeutics Corporate Events
Shield Therapeutics announced the initiation of a Phase II clinical trial in Japan for ACCRUFeR® (ferric maltol) as a treatment for Pulmonary Arterial Hypertension (PAH). This trial, conducted by its partner MEDLEAP Pharma, aims to support a Phase III trial and potential regulatory submissions by 2028. The development is significant as it addresses the challenges of long-term iron supplementation in PAH patients, potentially positioning ACCRUFeR® as a core treatment in this field.
The most recent analyst rating on (GB:STX) stock is a Buy with a £0.10 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Shield Therapeutics announced the presentation of pediatric pharmacokinetic results for ferric maltol at the upcoming American Society of Hematology Conference. The study confirmed the suitability of ferric maltol for iron replacement in children, supporting its potential expansion to younger populations and highlighting its importance in addressing unmet medical needs in pediatric iron deficiency treatment.
The most recent analyst rating on (GB:STX) stock is a Buy with a £0.10 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Shield Therapeutics has announced that its product, ACCRUFeR®, has received marketing authorization from the Korean Ministry of Food and Drug Safety for treating iron deficiency in adults. This approval, following a successful pharmacokinetic study and new drug application by Korea Pharma, signifies a major advancement in expanding ACCRUFeR®’s availability in South Korea. Shield is set to receive payments and royalties from sales in the region, reinforcing its commitment to global patient access and highlighting the strength of its international partnerships.
The most recent analyst rating on (GB:STX) stock is a Buy with a £0.10 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Shield Therapeutics reported its strongest quarterly performance to date, with a 15% increase in ACCRUFeR® prescriptions over the previous quarter, achieving net revenues of $13.1 million. The company remains on track to become cash flow positive by the end of 2025, driven by strategic marketing initiatives and strong sales efforts, marking a significant milestone in its operational progress.
The most recent analyst rating on (GB:STX) stock is a Buy with a £0.10 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Shield Therapeutics announced the grant of share options to its CEO, Anders Lundstrom, as part of the company’s Retention and Performance Share Plan. This move is part of Lundstrom’s annual equity grant, with options granted over 1,547,262 ordinary shares. The grant reflects Shield’s commitment to retaining key leadership as it continues to focus on its market-leading product, ACCRUFeR®, which addresses a significant unmet need in iron deficiency treatment. The company’s strategic positioning in the pharmaceutical industry is reinforced by its global licensing agreements and the growing market opportunity for its flagship product.
The most recent analyst rating on (GB:STX) stock is a Buy with a £0.10 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Shield Therapeutics has announced that its total issued share capital consists of 1,061,802,812 ordinary shares, each with equal voting rights, as per FCA’s Disclosure and Transparency Rule. The company’s flagship product, ACCRUFeR®, is the first FDA-approved oral iron treatment for iron deficiency, representing a significant market opportunity and addressing unmet medical needs.
The most recent analyst rating on (GB:STX) stock is a Hold with a £6.50 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Shield Therapeutics announced positive results from its Phase 3 pediatric trial of ferric maltol, presented at the American Association of Pediatrics Conference. The study demonstrated significant improvements in hemoglobin levels and a favorable safety profile, marking an important milestone for expanding ACCRUFeR®’s use in young children. This development could enhance Shield’s market position by addressing a critical unmet need for safe and effective oral iron treatments in pediatric populations.
The most recent analyst rating on (GB:STX) stock is a Hold with a £6.50 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Shield Therapeutics has successfully raised £1.5 million through a placing of new ordinary shares, driven by unsolicited institutional investor demand, to support the growth of its leading product, ACCRUFeR®, in the U.S. market. This financial move, which involved issuing shares at a premium, aims to strengthen the company’s working capital and broaden its shareholder base, positioning Shield to accelerate sales and achieve positive cash flow by the end of 2025.
The most recent analyst rating on (GB:STX) stock is a Hold with a £6.50 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Shield Therapeutics has announced that the FDA has accepted ACCRUFeR®/FeRACCRU® for Priority Review to extend its indication to adolescents with iron deficiency anemia, with approval anticipated in 2026. This development follows successful Phase 3 trials and could significantly expand the patient base, offering a novel oral treatment option for both adolescents and potentially adults who have difficulty swallowing capsules.
The most recent analyst rating on (GB:STX) stock is a Hold with a £6.50 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Shield Therapeutics reported a significant increase in revenues and prescription sales for the first half of 2025, driven by the strong performance of its product ACCRUFeR® in the U.S. and global markets. The company achieved substantial progress in international partnerships, including new licensing agreements and regulatory submissions, while maintaining its guidance to become cash flow positive by the end of 2025. These developments highlight Shield’s strategic efforts to expand its market presence and meet the growing demand for its iron deficiency treatment.
The most recent analyst rating on (GB:STX) stock is a Hold with a £6.50 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Shield Therapeutics announced positive results from the ORION-HF study, which demonstrated significant improvements in haemoglobin levels, exercise capacity, and quality of life for patients with heart failure and iron deficiency anemia treated with FeRACCRU® (ferric maltol). These findings, published in the European Journal of Heart Failure, highlight the potential of ferric maltol as an effective oral alternative to intravenous iron therapies, addressing a significant unmet need in the treatment of heart failure. The study’s results are consistent with previous research and could enhance Shield’s market positioning and stakeholder interest in the therapeutic benefits of ACCRUFeR®/FeRACCRU®.
The most recent analyst rating on (GB:STX) stock is a Hold with a £6.50 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.